Clinical Trial

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-08-19; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2022-11-09
Trial Details
NCT Number NCT05509933
Lead Sponsor Henry Ford Health System
Conditions Engraftment Syndrome
Enrollment 110 participants
Start Date 2022-11-09
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-01